Dual specificity mitogen-activated protein kinase kinase 2 Inhibitors (IC50, Ki)

Structure ▲ ▼	Compound Name ▲ ▼	Standard Type ▲ ▼	Standard Values (in nM) ▲ ▼
	1,4-Diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene	IC50	58.0 [1], 60.0 [2]
	(4S,6Z,9S,10S)-9,10,18-Trihydroxy-16-methoxy-4-methyl-3-oxabicyclo[12.4.0]octadeca-1(14),6,15,17-tetraene-2,8-dione	IC50	8.16 [1], 15.0 [2]
	2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	IC50	50000.0 [1]
	Trametinib	IC50	1.6 [1]
	(Z)-3-Amino-3-(4-aminophenylthio)-2-(2-(trifluoromethyl)phenyl)acrylonitrile	IC50	220.0 [1]
	Cyclohexanol, 4-(4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1H-imidazol-1-yl)-, trans-	IC50	50.0 [1]
	4-(4-(4-Fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)-2-methoxypyrimidine	IC50	50.0 [1]
	6-(5-Bromo-2-hydroxyphenyl)-2-oxo-4-phenyl-1,2-dihydropyridine-3-carbonitrile	IC50	20000.0 [1]
	5-Amino-6-[(Z)-(3-hydroxy-4-oxocyclohexa-2,5-dien-1-ylidene)methyl]-2-(4-hydroxyphenyl)-[1,3,4]thiadiazolo[3,2-a]pyrimidin-7-one	IC50	1300.0 [1]
	N-Propyl-4-({4-[(2,2,2-trifluoroethyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-2-yl}amino)benzamide	IC50	391.0 [1]
	4-Methyl-N-(1,2-oxazol-3-yl)-3-[(1-phenylpyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide	IC50	30000.0 [1]
	2-[3-[(Dimethylamino)methyl]phenyl]-4-[(4-methyl-1H-indol-5-yl)amino]thieno[2,3-b]pyridine-5-carbonitrile	IC50	20000.0 [1]
	5-(2-Amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-tert-butylpyridine-3-sulfonamide	IC50	10000.0 [1]
	N-Benzyl-2,2-dimethyl-N-[2-[[(2S)-1'-methyl-2',4'-dioxospiro[1,3-dihydroindene-2,5'-imidazolidine]-5-yl]amino]-2-oxoethyl]propanamide	Ki	710.0 [1]
	N-[(1R)-1-(3,5-Difluorophenyl)ethyl]-2,2-dimethyl-N-[2-[[(2S)-1'-methyl-2',4'-dioxospiro[1,3-dihydroindene-2,5'-imidazolidine]-5-yl]amino]-2-oxoethyl]propanamide	Ki	1400.0 [1]
	(4S,6Z)-18-Hydroxy-16-methoxy-4-methyl-3-oxabicyclo[12.4.0]octadeca-1(14),6,15,17-tetraene-2,8-dione	IC50	6840.0 [1]
	6-(2,4-Difluorophenyl)sulfonyl-2-(1H-indol-5-ylamino)-8-methylpyrido[2,3-d]pyrimidin-7-one	IC50	10000.0 [1]
	3-(5-Cyclopropyl-1,2-oxazol-3-yl)-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-4-amine	IC50	82.0 [1]
	(4S,9S,10S)-9,10,18-Trihydroxy-16-methoxy-4-methyl-3-oxabicyclo[12.4.0]octadeca-1(14),15,17-triene-2,8-dione	IC50	186.7 [1]
	5,5-Dimethyl-8-[[4-(2,2,2-trifluoroethylamino)furo[3,2-d]pyrimidin-2-yl]amino]-1H-4,1-benzoxazepin-2-one	IC50	10000.0 [1]
	N-[(3-Methoxyphenyl)methyl]-2,2-dimethyl-N-[2-[(1'-methyl-2',4'-dioxospiro[1,3-dihydroindene-2,5'-imidazolidine]-5-yl)amino]-2-oxoethyl]propanamide	Ki	9700.0 [1]
	N-[(3-Cyanophenyl)methyl]-2,2-dimethyl-N-[2-[(1'-methyl-2',4'-dioxospiro[1,3-dihydroindene-2,5'-imidazolidine]-5-yl)amino]-2-oxoethyl]propanamide	Ki	13000.0 [1]
	2,2-Dimethyl-N-[2-[(1'-methyl-2',4'-dioxospiro[1,3-dihydroindene-2,5'-imidazolidine]-5-yl)amino]-2-oxoethyl]-N-[[4-(trifluoromethyl)phenyl]methyl]propanamide	Ki	6200.0 [1]
	N-[(3,5-Difluorophenyl)methyl]-2,2-dimethyl-N-[2-[[(2S)-1'-methyl-2',4'-dioxospiro[1,3-dihydroindene-2,5'-imidazolidine]-5-yl]amino]-2-oxoethyl]propanamide	Ki	2400.0 [1]
	N-[(3-Fluorophenyl)methyl]-2,2-dimethyl-N-[2-[(1'-methyl-2',4'-dioxospiro[1,3-dihydroindene-2,5'-imidazolidine]-5-yl)amino]-2-oxoethyl]propanamide	Ki	1400.0 [1]
	N-[(3-Chloro-5-fluorophenyl)methyl]-2,2-dimethyl-N-[2-[[(2S)-1'-methyl-2',4'-dioxospiro[1,3-dihydroindene-2,5'-imidazolidine]-5-yl]amino]-2-oxoethyl]propanamide	Ki	1800.0 [1]
	N-[(4-Fluorophenyl)methyl]-2,2-dimethyl-N-[2-[(1'-methyl-2',4'-dioxospiro[1,3-dihydroindene-2,5'-imidazolidine]-5-yl)amino]-2-oxoethyl]propanamide	Ki	3700.0 [1]
	N-[(3-Chlorophenyl)methyl]-2,2-dimethyl-N-[2-[(1'-methyl-2',4'-dioxospiro[1,3-dihydroindene-2,5'-imidazolidine]-5-yl)amino]-2-oxoethyl]propanamide	Ki	1400.0 [1]
	2,2-Dimethyl-N-[2-[(1'-methyl-2',4'-dioxospiro[1,3-dihydroindene-2,5'-imidazolidine]-5-yl)amino]-2-oxoethyl]-N-[(3-methylphenyl)methyl]propanamide	Ki	1800.0 [1]
	N-[(3,5-Dichlorophenyl)methyl]-2,2-dimethyl-N-[2-[[(2S)-1'-methyl-2',4'-dioxospiro[1,3-dihydroindene-2,5'-imidazolidine]-5-yl]amino]-2-oxoethyl]propanamide	Ki	2100.0 [1]
	2,2-Dimethyl-N-[2-[[(2S)-1'-methyl-2',4'-dioxospiro[1,3-dihydroindene-2,5'-imidazolidine]-5-yl]amino]-2-oxoethyl]-N-[(1S)-1-phenylethyl]propanamide	Ki	16000.0 [1]
	2,2-Dimethyl-N-[2-[[(2S)-1'-methyl-2',4'-dioxospiro[1,3-dihydroindene-2,5'-imidazolidine]-5-yl]amino]-2-oxoethyl]-N-[(1R)-1-phenylethyl]propanamide	Ki	670.0 [1]
	2-N-(1H-Indazol-6-yl)-4-N-(2,2,2-trifluoroethyl)furo[3,2-d]pyrimidine-2,4-diamine	IC50	10000.0 [1]
	N~4~-Cyclopropyl-N~2~-(3-Methyl-1h-Indazol-6-Yl)furo[3,2-D]pyrimidine-2,4-Diamine	IC50	10000.0 [1]
	2-N-(3-Chloro-4-morpholin-4-ylphenyl)-4-N-(2,2,2-trifluoroethyl)furo[3,2-d]pyrimidine-2,4-diamine	IC50	10000.0 [1]

Entire TableStructureCompound NameStandard TypeStandard Values (in nM)

Items per page: 510All1 - 10 of 35 ⟨⟩

---

---

References

This online tool may be cited as follows

MLA	"Quest Database™ Dual specificity mitogen-activated protein kinase kinase 2 Inhibitors (IC50, Ki)." AAT Bioquest, Inc., 21 Feb. 2025, https://www.aatbio.com/data-sets/dual-specificity-mitogen-activated-protein-kinase-kinase-2-inhibitors-ic50-ki.
APA	AAT Bioquest, Inc. (2025, February 21). Quest Database™ Dual specificity mitogen-activated protein kinase kinase 2 Inhibitors (IC50, Ki). AAT Bioquest. https://www.aatbio.com/data-sets/dual-specificity-mitogen-activated-protein-kinase-kinase-2-inhibitors-ic50-ki.
BibTeX	EndNote	RefMan